Insider Selling: Phreesia, Inc. (NYSE:PHR) COO Sells 2,873 Shares of Stock

Phreesia, Inc. (NYSE:PHR) COO Evan Roberts sold 2,873 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $26.61, for a total value of $76,450.53. Following the completion of the sale, the chief operating officer now owns 779,993 shares of the company’s stock, valued at approximately $20,755,613.73. This trade represents a 0.37 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Evan Roberts also recently made the following trade(s):

• On Tuesday, October 15th, Evan Roberts sold 1,843 shares of Phreesia stock. The stock was sold at an average price of $21.03, for a total transaction of $38,758.29.

Phreesia Stock Up 5.3 %

Shares of PHR traded up $1.44 during trading hours on Wednesday, reaching $28.42. The company’s stock had a trading volume of 668,317 shares, compared to its average volume of 410,783. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of -19.33 and a beta of 0.94. The company has a quick ratio of 1.77, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The company has a 50 day moving average of $22.30 and a two-hundred day moving average of $22.49. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $29.16.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The business had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. During the same period last year, the company earned ($0.58) earnings per share. Phreesia’s quarterly revenue was up 16.6% compared to the same quarter last year. As a group, research analysts predict that Phreesia, Inc. will post -1.16 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. KeyCorp lifted their price objective on shares of Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Wednesday. Truist Financial lifted their price target on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Royal Bank of Canada raised Phreesia from a “sector perform” rating to an “outperform” rating and raised their price objective for the stock from $24.00 to $32.00 in a research note on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 target price on shares of Phreesia in a research report on Tuesday, December 10th. Finally, Robert W. Baird decreased their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Eleven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $30.64.

Hedge Funds Weigh In On Phreesia

Hedge funds have recently added to or reduced their stakes in the company. International Assets Investment Management LLC increased its stake in shares of Phreesia by 2,179.7% during the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock worth $33,000 after purchasing an additional 1,395 shares during the last quarter. Lombard Odier Asset Management USA Corp bought a new position in Phreesia during the second quarter valued at about $202,000. Point72 DIFC Ltd bought a new stake in shares of Phreesia during the 2nd quarter worth about $209,000. XTX Topco Ltd bought a new position in shares of Phreesia in the 3rd quarter valued at approximately $247,000. Finally, Hsbc Holdings PLC acquired a new stake in Phreesia in the 2nd quarter worth approximately $301,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.